PL2694038T3 - Kompozycja farmaceutyczna - Google Patents

Kompozycja farmaceutyczna

Info

Publication number
PL2694038T3
PL2694038T3 PL12713721T PL12713721T PL2694038T3 PL 2694038 T3 PL2694038 T3 PL 2694038T3 PL 12713721 T PL12713721 T PL 12713721T PL 12713721 T PL12713721 T PL 12713721T PL 2694038 T3 PL2694038 T3 PL 2694038T3
Authority
PL
Poland
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
PL12713721T
Other languages
English (en)
Inventor
Brkicic Ljiljana Sovic
Zdravko Dokuzovic
Original Assignee
Brkicic Ljiljana Sovic
Brkicic Cvjetko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brkicic Ljiljana Sovic, Brkicic Cvjetko filed Critical Brkicic Ljiljana Sovic
Publication of PL2694038T3 publication Critical patent/PL2694038T3/pl

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D1/00—Processes for applying liquids or other fluent materials
    • B05D1/18—Processes for applying liquids or other fluent materials performed by dipping
    • B05D1/22—Processes for applying liquids or other fluent materials performed by dipping using fluidised-bed technique
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D1/00—Processes for applying liquids or other fluent materials
    • B05D1/02—Processes for applying liquids or other fluent materials performed by spraying

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL12713721T 2011-04-06 2012-04-05 Kompozycja farmaceutyczna PL2694038T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11161398A EP2508174A1 (en) 2011-04-06 2011-04-06 Pharmaceutical composition
PCT/EP2012/056366 WO2012136816A2 (en) 2011-04-06 2012-04-05 Pharmaceutical composition
EP12713721.4A EP2694038B1 (en) 2011-04-06 2012-04-05 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
PL2694038T3 true PL2694038T3 (pl) 2019-10-31

Family

ID=44454073

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12713721T PL2694038T3 (pl) 2011-04-06 2012-04-05 Kompozycja farmaceutyczna

Country Status (21)

Country Link
US (1) US11103891B2 (pl)
EP (3) EP2508174A1 (pl)
JP (2) JP6144252B2 (pl)
KR (1) KR102078885B1 (pl)
CN (1) CN103517708B (pl)
AP (1) AP3864A (pl)
AU (2) AU2012238629A1 (pl)
BR (1) BR112013025519B1 (pl)
CA (1) CA2832130C (pl)
DK (1) DK2694038T3 (pl)
EA (1) EA030074B1 (pl)
ES (1) ES2743130T3 (pl)
HR (1) HRP20191555T1 (pl)
HU (1) HUE045928T2 (pl)
LT (1) LT2694038T (pl)
MX (1) MX352934B (pl)
PL (1) PL2694038T3 (pl)
PT (1) PT2694038T (pl)
RS (1) RS59061B1 (pl)
SI (1) SI2694038T1 (pl)
WO (1) WO2012136816A2 (pl)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ602302A (en) 2007-12-28 2014-04-30 Impax Laboratories Inc Controlled release formulations of levodopa and uses thereof
MX353096B (es) 2010-08-19 2017-12-19 Buck Institute For Age Res Star Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados.
EP3181128B1 (en) * 2012-01-13 2023-03-08 XSpray Pharma AB (publ) Nilotinib pharmaceuticalcomposition
US20150030683A1 (en) * 2012-02-18 2015-01-29 Buck Institute For Research On Aging Formulations and methods for the treatment or prophylaxis of pre-mci and/or pre-alzheimer's conditions
EP2725072B1 (en) * 2012-10-25 2015-07-22 Rohm and Haas Company Aldehyde abatement with porous amine functional resins
ES2502140T1 (es) * 2013-02-06 2014-10-02 Galenicum Health S.L. Comprimidos de liberación inmediata de rasagilina hemitartrato
WO2014142938A1 (en) * 2013-03-15 2014-09-18 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
WO2014180912A1 (en) * 2013-05-08 2014-11-13 Sanovel Ilac Sanayi Ve Ticaret A.S. Modified release formulations of lacosamide
CN104146978B (zh) * 2013-05-13 2016-12-28 沈阳药科大学 一种双硫仑肠溶片剂及其制备方法
CN105377842A (zh) 2013-07-25 2016-03-02 巴斯夫欧洲公司 呈无定形形式的达沙替尼的盐
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
CN105658211A (zh) * 2013-10-07 2016-06-08 怡百克制药公司 左旋多巴和/或左旋多巴的酯的粘膜粘附性、控制释放调配物和其用途
CN103622942A (zh) * 2013-11-04 2014-03-12 江苏大学 左旋多巴/卡比多巴复方缓释混悬剂及其制备方法
FR3017533B1 (fr) * 2014-02-19 2016-03-11 Cousin Biotech Dispositif implantable, notamment pour la refection de paroi abdominale
JP6577024B2 (ja) * 2014-05-08 2019-09-18 シーティーシー バイオ インコーポレイテッド 味が遮蔽されたクロミプラミン含有経口投与用薬学製剤
WO2015170939A1 (ko) * 2014-05-08 2015-11-12 주식회사 씨티씨바이오 클로미프라민 함유 맛 차폐된 구강 투여용 약학 제제
US20150110871A1 (en) * 2014-06-02 2015-04-23 David Wong Gastric retentive tablet compositions
ES2908142T3 (es) * 2014-06-13 2022-04-27 United Therapeutics Corp Formulaciones de treprostinil
WO2016014242A1 (en) * 2014-07-21 2016-01-28 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy n-substituted-2-aminotetralins, dosage forms, and related methods
US20150133464A1 (en) * 2015-02-01 2015-05-14 David Wong Injectable particle
JP6876003B2 (ja) 2015-02-27 2021-05-26 デクラ リミテッド イヌ及びネコにおける、食欲の刺激、体重減少の管理、及び拒食症の処置
CN113197851A (zh) 2015-05-06 2021-08-03 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
CN105223326B (zh) * 2015-09-23 2017-01-18 天津中医药大学 一种中药口服速释制剂中活性成分的体外分类方法
CN105310980A (zh) * 2015-10-09 2016-02-10 北京万全德众医药生物技术有限公司 帕利哌酮缓释混悬口服液及其制备方法
CN105902500B (zh) * 2016-04-27 2019-11-29 上海理工大学 一种美沙拉嗪肠溶定位控释制剂及其制备方法
WO2018062955A1 (ko) * 2016-09-29 2018-04-05 에스케이케미칼(주) 라코사미드 서방성 제제
GR1009209B (el) 2016-11-17 2018-02-05 Φαρματεν Αβεε Φαρμακευτικο σκευασμα περιεχον εναν αντιεμετικο παραγοντα και μεθοδος για την παρασκευη αυτου
CN107049985B (zh) * 2017-06-07 2020-06-19 广州帝奇医药技术有限公司 一种抗帕金森病药物的长效缓释制剂及其制备方法
EP3681491A4 (en) 2017-09-11 2021-06-30 Atossa Therapeutics, Inc. PROCESS FOR MANUFACTURING AND USE OF ENDOXIFES
AU2018379992B2 (en) 2017-12-05 2022-07-21 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
CN112236138B (zh) 2017-12-05 2024-05-31 赛诺维信制药公司 晶体形式及其制备方法
CN108186563A (zh) * 2017-12-06 2018-06-22 江苏大学 苯妥英钠缓释混悬剂及其制备方法
EP3727339A1 (en) * 2017-12-22 2020-10-28 DDP Specialty Electronic Materials US, Inc. Pharmaceutical composition containing resin particles
CN108057134B (zh) * 2017-12-26 2020-12-01 湖北回盛生物科技有限公司 一种奶牛助产润滑剂及其制备方法
US10835489B2 (en) 2018-03-09 2020-11-17 University Of Saskatchewan Modified release formulations of mycophenolate mofetil
CN108553437A (zh) * 2018-06-08 2018-09-21 姚静 一种通过离子交换技术制得的巯嘌呤咀嚼片及其制备方法
TWI787523B (zh) 2018-06-15 2022-12-21 漢達生技醫藥股份有限公司 達沙替尼十二烷基硫酸鹽之結晶
WO2020101586A1 (en) 2018-11-16 2020-05-22 Santa Farma İlaç Sanayi̇ A.Ş. Controlled release propiverine formulations
CN109966277B (zh) * 2019-05-23 2021-04-30 济宁医学院附属医院 一种治疗难治性癫痫的药物组合物及其应用
CA3142355A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
WO2021003433A1 (en) * 2019-07-03 2021-01-07 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
CN110974813B (zh) * 2019-12-06 2021-04-06 四川大学华西医院 奥西那林在抗菌药物中的应用及筛选抗菌药物的方法
CN111494316B (zh) * 2020-04-14 2021-05-18 山东大学 一种载双硫仑的纳米乳原位凝胶剂的制备方法及其应用
CN111840240A (zh) * 2020-05-29 2020-10-30 仁和堂药业有限公司 一种非那雄胺制剂及其应用
CN111840255B (zh) * 2020-07-31 2022-03-01 北京丰帆生物医药科技有限公司 一种维拉帕米温敏缓释制剂及其制备方法和应用
CN112353767A (zh) * 2020-11-16 2021-02-12 海南锦瑞制药有限公司 一种盐酸地尔硫卓和普瑞巴林组合物及其制备方法及其应用
CN112190573A (zh) * 2020-11-17 2021-01-08 四川大学华西医院 一种治疗肝癌的联合用药物
US12194150B2 (en) 2020-12-22 2025-01-14 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
EP4469027A4 (en) * 2022-01-26 2025-11-12 Tulex Pharmaceuticals Inc NEW COMPOSITIONS
CN121154589A (zh) * 2024-07-08 2025-12-19 中国医科大学 磷酸卡维地洛树脂缓释微囊及其制备方法和应用
CN121015576A (zh) * 2025-09-16 2025-11-28 宁波大红鹰药业股份有限公司 一种含盐酸苯海索的药物组合物及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT629516A (pl) 1959-04-30
US3117027A (en) 1960-01-08 1964-01-07 Wisconsin Alumni Res Found Apparatus for coating particles in a fluidized bed
US3253944A (en) 1964-01-13 1966-05-31 Wisconsin Alumni Res Found Particle coating process
US4221778A (en) 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
US4361545A (en) 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
US4847077A (en) 1984-07-18 1989-07-11 Pennwalt Corporation Controlled release pharmaceutical preparations
ZA889189B (en) 1986-06-16 1989-08-30 Merck & Co Inc Controlled release combination of carbidopa/levodopa
US4832957A (en) 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4983400A (en) 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4859462A (en) * 1986-07-30 1989-08-22 Fisons Corporation Polymer-treated ion exchange resins
NZ219925A (en) * 1986-07-30 1989-06-28 Pennwalt Corp Polymer-treated sulphonic acid cationic exchange resin particles
US4859461A (en) 1986-07-30 1989-08-22 Fisons Corporation Coatable ion exchange resins
JPS63101332A (ja) * 1986-10-17 1988-05-06 Sato Seiyaku Kk 経口投与用徐放性製剤
US4894239A (en) * 1987-06-02 1990-01-16 Takeda Chemical Industries, Ltd. Sustained-release preparation and production thereof
EP0324947B2 (de) * 1987-12-31 1997-08-20 ASTA Medica Aktiengesellschaft Synergistische Kombination von Decarboxylasehemmern und L-Dopa-Pellets
US4959219A (en) 1988-08-15 1990-09-25 Fisons Corporation Coating barriers comprising ethyl cellulose
TW209174B (pl) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
IT1255522B (it) 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
KR0178099B1 (ko) 1996-08-22 1999-03-20 정도언 방출제어형 이부프로펜 과립제 및 그의 제조방법
AU736308B2 (en) 1996-12-20 2001-07-26 Warner-Lambert Company Llc Antitussive drugs delivered by ion exchange resins
IT1295271B1 (it) 1997-10-03 1999-05-04 Chiesi Farma Spa Monolita contenente uno o piu'farmaci costituito da tre strati a meccanismo di rilascio differenziato
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20030099711A1 (en) * 2001-08-29 2003-05-29 David Meadows Sustained release preparations
US20030224045A1 (en) 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
EP1572201B1 (en) 2002-12-18 2008-07-09 Ferrer Internacional, S.A. Pharmaceutical compositions of sertaconazole for vaginal use
AU2004207578B2 (en) * 2003-01-28 2007-06-28 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
AU2004229478B2 (en) * 2003-04-10 2009-12-24 3M Innovative Properties Company Delivery of immune response modifier compounds
US20050181050A1 (en) * 2004-01-28 2005-08-18 Collegium Pharmaceutical, Inc. Dosage forms using drug-loaded ion exchange resins
US20070036843A1 (en) * 2005-01-28 2007-02-15 Collegium Pharmaceutical, Inc. Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents
EP1901720A2 (en) * 2005-06-23 2008-03-26 Spherics, Inc. Improved dosage forms for movement disorder treatment
KR20090057349A (ko) 2006-05-31 2009-06-05 솔베이 파머슈티컬스 게엠베하 레보도파/칼비도파의 24시간의 장기간 장내투여
BRPI0719021A2 (pt) * 2006-11-21 2013-12-17 Mcneil-Ppc, Inc. Suspensões analgésicas de liberação modificada.
CA2689101C (en) * 2007-05-30 2013-01-22 Neos Therapeutics, Lp Modifying drug release in suspensions of ionic resin systems

Also Published As

Publication number Publication date
JP2017125028A (ja) 2017-07-20
HRP20191555T1 (hr) 2019-11-29
PT2694038T (pt) 2019-08-01
US20140154328A1 (en) 2014-06-05
EP2694038A2 (en) 2014-02-12
KR102078885B1 (ko) 2020-02-18
EP3607938A3 (en) 2020-04-22
HUE045928T2 (hu) 2020-01-28
JP6144252B2 (ja) 2017-06-07
ES2743130T3 (es) 2020-02-18
LT2694038T (lt) 2019-08-26
US11103891B2 (en) 2021-08-31
AP2013007227A0 (en) 2013-11-30
EP2508174A1 (en) 2012-10-10
RS59061B1 (sr) 2019-08-30
AU2017203939B2 (en) 2019-05-30
EA201391483A1 (ru) 2014-05-30
EP3607938B1 (en) 2026-05-27
CN103517708B (zh) 2016-02-17
EP2694038B1 (en) 2019-05-29
WO2012136816A3 (en) 2013-01-31
MX2013011572A (es) 2014-05-21
CA2832130A1 (en) 2012-10-11
WO2012136816A2 (en) 2012-10-11
AU2012238629A1 (en) 2013-11-21
EA030074B1 (ru) 2018-06-29
BR112013025519A2 (pt) 2017-12-12
BR112013025519B1 (pt) 2022-02-01
CN103517708A (zh) 2014-01-15
MX352934B (es) 2017-12-14
AU2017203939A1 (en) 2017-07-06
SI2694038T1 (sl) 2019-10-30
EP3607938A2 (en) 2020-02-12
EP3607938C0 (en) 2026-05-27
DK2694038T3 (da) 2019-08-19
AP3864A (en) 2016-10-31
JP2014510128A (ja) 2014-04-24
CA2832130C (en) 2019-04-23
KR20140029435A (ko) 2014-03-10

Similar Documents

Publication Publication Date Title
AP3864A (en) Pharmaceutical composition
GB201113662D0 (en) Pharmaceutical compositions
AP3656A (en) Pharmaceutical compositions
ZA201308208B (en) Pharmaceutical compositions
GB201118232D0 (en) Pharmaceutical composition
SI2776416T1 (sl) Farmacevtske spojine
ZA201501930B (en) Pharmaceutical composition
EP2832730A4 (en) MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
ZA201308157B (en) Pharmaceutical composition
HUE045030T2 (hu) Diklofenak összetétel
GB201119799D0 (en) Pharmaceutical compounds
ZA201403832B (en) Pharmaceutical compounds
GB201118876D0 (en) Pharmaceutical compounds
GB201113163D0 (en) Pharmaceutical compounds
EP2727593A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING NICORANDIL
GB201118181D0 (en) Pharmaceutical compositions
EP2711010A4 (en) PHARMACEUTICAL COMPOSITION
ZA201502987B (en) Pharmaceutical composition
HUP1100444A2 (en) Pharmaceutical composition
ZA201308414B (en) Solid pharmaceutical composition
HUP1100445A2 (en) Pharmaceutical composition
ZA201309537B (en) Pharmaceutical composition comprising fexofedine
GB201105224D0 (en) Novel pharmaceutical compositions
ZA201400751B (en) Pharmaceutical composition
GB201119796D0 (en) Pharmaceutical comopounds